Detalhe da pesquisa
1.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980367
2.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Cancer Immunol Immunother
; 73(4): 72, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430405
3.
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.
Blood
; 140(13): 1533-1548, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895896
4.
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.
Proc Natl Acad Sci U S A
; 118(13)2021 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33753479
5.
Experience with the US health care system for Black and White patients with advanced prostate cancer.
Cancer
; 129(16): 2532-2541, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246339
6.
The Value of Phenotypic Precision Medicine in Prostate Cancer.
Oncologist
; 28(2): 93-104, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200788
7.
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.
Oncologist
; 2023 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37368355
8.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
N Engl J Med
; 382(23): 2187-2196, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469183
9.
New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Expert Rev Mol Med
; 25: e18, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37154101
10.
Hospital-Based Community Gardens as a Strategic Partner in Addressing Community Health Needs.
Am J Public Health
; 113(9): 939-942, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37348038
11.
Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?
Future Oncol
; 19(31): 2075-2082, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646326
12.
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
Qual Life Res
; 32(11): 3209-3221, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37410340
13.
Remethylation of Dnmt3a-/- hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing.
Proc Natl Acad Sci U S A
; 117(6): 3123-3134, 2020 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31996479
14.
The transformative power of participating in Opening Minds Through Art (OMA), an expressive arts program for medical students.
Gerontol Geriatr Educ
; : 1-13, 2023 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37722717
15.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 362-373, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131040
16.
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
Prostate
; 82(7): 858-866, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286730
17.
Racial disparities in Black men with prostate cancer: A literature review.
Cancer
; 128(21): 3787-3795, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066378
18.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Cancer
; 128(5): 966-974, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784056
19.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet
; 397(10275): 695-703, 2021 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33592176
20.
Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?
Future Oncol
; 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226872